About Colt Ventures
Colt Ventures is a private equity firm founded in 2003. It is primarily based in Dallas, United States.
Overall Colt Ventures portfolio has seen 27 IPOs and 21 acquisitions, namely Deliveroo, ServiceNow and Alnylam. A lot of funds co-invest with Colt Ventures, with names like Orbimed sharing a substantial percentage of its portfolio.
Colt Ventures has a team of 2 people, including 1 partner.
Key Metrics
Colt Ventures' Portfolio
They have invested in a total of 61 companies. Their most recent investment was in BlossomHill Therapeutics (Series B round) on Dec 28, 2023. Here is the most recent investment by Colt Ventures:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Dec 28, 2023 | Series B | 1808 | ||
Oct 25, 2023 | Series C | 3644 | ||
Nov 02, 2022 | Series A | 7104 | ||
Oct 13, 2022 | Series B | 9374 |
Here is the portfolio snapshot of Colt Ventures:
Investments by Year
The maximum number of investments were made in 2023
Team profile of Colt Ventures
Colt Ventures has a team of 2 members located in United States. Colt Ventures' team does not sit on the board of any company as of now.Co-investors of Colt Ventures
Over the past 23 years, 28 investors have co-invested in Colt Ventures's portfolio companies.
- Top Co-investors of Colt Ventures: 28 investors entered a company along with Colt Ventures. These include investors like Orbimed (3 companies).
Colt Ventures News
•
ColdVentures Unveils FDA-Approved ColdVest to Prevent Heat-Related DeathsHIT Consultant•Jun 21, 2024•Colt Ventures
•
•
BlossomHill secures $100m for cancer discovery programmesPharmaceutical Technology•Mar 01, 2024•BlossomHill Therapeutics, Colt Ventures, Orbimed, Cormorant Asset Management and 2 others
•
BlossomHill Therapeutics Closes $100 Million Series B FinancingBusiness Wire•Feb 29, 2024•BlossomHill Therapeutics, Colt Ventures, Cormorant Capital, Orbimed and 5 others
•
Ability Biologics: Cell Targeting Company Raises $12 MillionPulse 2.0•Dec 18, 2023•AbilityPharma, Amplitude, Charles River Laboratories, Alexandria and 17 others
•
Odyssey Therapeutics Announces $101 Million Series C FinancingBusiness Wire•Dec 05, 2023•Odyssey, Ascenta Capital, Orbimed, SR One and 10 others
•
Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer TherapiesBusiness Wire•Nov 02, 2022•Boxer Capital, Alterome Therapeutics, Colt Ventures, Orbimed and 2 others
•
Odyssey recruits news investors to fund precision drug researchBioPharmaDive•Oct 13, 2022•Odyssey, Fidelity Investments, General Catalyst, T. Rowe Price and 14 others
•
Odyssey Therapeutics Raises $218M in Series A FinancingFinSMEs•Dec 08, 2021•Odyssey, Orbimed, SR One, Foresite Capital and 5 others
•
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 MillionBusiness Wire•Oct 21, 2021•ReCode Therapeutics, Pfizer, Sanofi Ventures, Tekla Capital Management and 8 others
